Therapy Areas: Oncology
US FDA extends review timeline for AstraZeneca's camizestrant application
27 May 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Wednesday that the US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee...
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)
27 May 2026 - Rare disease pharmacy solutions provider Orsini announced on Tuesday that it is the contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod) 8.5 mg, a subcutaneous in...
OncoZenge secures European approval for Phase III BEAM-Pain trial of BupiZenge
26 May 2026 - Swedish pharmaceutical company OncoZenge AB (Nasdaq First North Growth Market:ONCOZ) announced on Tuesday that it has received European regulatory approval to initiate its pivotal Phase ...
Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases
26 May 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Tuesday that it will present new preclinical data on its TG-MVA prophylactic vaccine candidates against mpox at the Wor...
Pierre Fabre Laboratories' BRAFTOVI (encorafenib) combination receives CHMP positive opinion in BRAFV600E-mutant mCRC
26 May 2026 - French pharmaceutical company Pierre Fabre Laboratories announced on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issu...
Menarini Group to present new elacestrant and tagraxofusp data at ASCO 2026 Annual Meeting
26 May 2026 - Italian pharmaceutical and diagnostics company the Menarini Group and its subsidiary Stemline Therapeutics Inc announced on Monday that new data related to elacestrant and tagraxofusp wi...